As of 2026-03-16, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 15.5x | 14.4x |
| Forward P/E multiples | 16.1x - 21.1x | 18.8x |
| Fair Price | (51.98) - (50.16) | (53.65) |
| Upside | -126.0% - -125.1% | -126.8% |
| Date | EV/EBITDA |